Dova Pharmaceuticals Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Companyâ€™s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD). The Companyâ€™s product candidate, avatrombopag is an orally administered thrombopoietin receptor agonist, or TPO-RA. The Company has completed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with CLD. The Company has not generated any revenue.

Employees

Sector

Biotechnology & Medical Research

More about the company

Delayed Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-0.07%	+269.92%

09/12/19	Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study - Core and Extension Phase - with Avatrombopag	CI
09/12/19	Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study Core and Extension Phase	CI

Market Cap	808M 708M 654M 604M 1.15B 77.33B 1.17B 7.86B 3.05B 37.84B 3.03B 2.97B 131B	P/E 2017	-20.6x	P/E 2018	-2.92x
Enterprise Value	723M 634M 586M 541M 1.03B 69.25B 1.05B 7.04B 2.74B 33.89B 2.72B 2.66B 118B	EV / Sales 2017	-	EV / Sales 2018	12,500,634x
Free-Float	48.06%	Yield 2017 *	-	Yield 2018	-

09/12/19	Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study - Core and Extension Phase - with Avatrombopag	CI
09/12/19	Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study Core and Extension Phase	CI
09/12/19	Dova Pharmaceuticals Demonstrates Cost-Effectiveness of Doptelet (Avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease	CI
05/12/19	Sobi and Dova Pharmaceuticals to Present New Data from Studies with Avatrombopag for the Treatment of Thrombocytopenia in Adult Patients with Chronic Liver Disease as Well as Patients with Chronic Immune Thrombocytopenia	CI
13/11/19	Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from NASDAQ Composite Index	CI
12/11/19	Dova Pharmaceuticals, Inc. Announces Executive Changes	CI
12/11/19	Dova Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
12/11/19	Swedish Orphan Biovitrum AB (OM:SOBI) completed the acquisition of Dova Pharmaceuticals, Inc. from Paul B. Manning, Sean Stalfort and other shareholders.	CI
11/11/19	Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from S&P TMI Index	CI
11/11/19	Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from S&P Global BMI Index	CI
11/11/19	Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from NASDAQ Biotechnology Index	CI
30/09/19	Swedish Orphan Biovitrum AB (OM:SOBI) entered into a definitive agreement to acquire Dova Pharmaceuticals, Inc. from Paul B. Manning, Sean Stalfort, and other shareholders for approximately $790 million.	CI
06/08/19	Dova Pharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 06, 2019

05/10/19	WeissLaw LLP Investigates Dova Pharmaceuticals, Inc.	PR
01/10/19	Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) on Behalf of Dova Shareholders and Encourages Dova Investors to Contact the Firm	PR
30/09/19	Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Dova Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Swedish Orphan Biovitrum AB	PR
30/09/19	Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi)	GL
26/09/19	Dova Pharmaceuticals to Present at 2019 Cantor Global Healthcare Conference	GL

Dova Pharmaceuticals, Inc. Stock

Stocks

DOVA

US25985T1025

Biotechnology & Medical Research

Valuation: Dova Pharmaceuticals, Inc.

Latest news : Dova Pharmaceuticals, Inc.

Press Releases: Dova Pharmaceuticals, Inc.

Managers and Directors: Dova Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Lee F. Allen CTO	Chief Tech/Sci/R&D Officer	74	01/04/2017
Stephen Crane SAM	Sales & Marketing	-	-
Caroline Diaz LAW	General Counsel	-	-

Director	Title	Age	Since
Henrik Stenqvist BRD	Director/Board Member	59	12/11/2019
Per Richard Torbjörn Hallberg BRD	Director/Board Member	57	12/11/2019
Guido Oelkers BRD	Director/Board Member	61	12/11/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DOVA PHARMACEUTICALS, INC.	-.--%	-0.07%	-	-	808M
ARGENX SE	-1.53%	-1.43%	+71.67%	+129.70%	57.72B
WUXI APPTEC CO., LTD.	-2.45%	-7.32%	+65.23%	+83.15%	52.65B
INSMED INCORPORATED	+3.27%	+8.91%	+21.21%	+471.23%	24.46B
BIONTECH SE	-0.81%	+0.52%	-15.01%	-12.47%	23.84B
WUXI BIOLOGICS (CAYMAN) INC.	-3.05%	+3.06%	+42.36%	-5.66%	19.28B
GENMAB A/S	-0.24%	+5.11%	+38.76%	-25.95%	17.8B
PHARMAESSENTIA CORPORATION	+2.34%	+14.18%	+220.96%	+380.99%	17.29B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-6.73%	+9.90%	+36.04%	-	15.28B
EXELIXIS, INC.	-1.70%	+3.98%	+28.96%	+194.23%	14.35B
Average	-1.09%	+4.67%	+56.69%	+151.90%	24.35B
Weighted average by Cap.	-1.26%	+2.70%	+57.79%	+140.26%

	2017	2018
Net sales	-	10.36 9.08 8.39 7.75 14.69 991.51 14.98 100.8 39.17 485.21 38.89 38.03 1.68K
Net income	-29.96M -26.27M -24.26M -22.42M -42.49M -2.87B -43.34M -292M -113M -1.4B -112M -110M -4.87B	-72.28M -63.4M -58.53M -54.09M -103M -6.92B -105M -704M -273M -3.39B -271M -265M -11.76B
Net Debt	-64.53M -56.6M -52.26M -48.29M -91.53M -6.18B -93.36M -628M -244M -3.02B -242M -237M -10.5B	-84.34M -73.98M -68.3M -63.11M -120M -8.08B -122M -821M -319M -3.95B -317M -310M -13.72B